EVFM vs. SBFM, BLPH, EVLO, ADTX, SPRC, SXTC, ATHX, CMRA, APVO, and AMPE
Should you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include Sunshine Biopharma (SBFM), Bellerophon Therapeutics (BLPH), Evelo Biosciences (EVLO), Aditxt (ADTX), SciSparc (SPRC), China SXT Pharmaceuticals (SXTC), Athersys (ATHX), Comera Life Sciences (CMRA), Aptevo Therapeutics (APVO), and Ampio Pharmaceuticals (AMPE). These companies are all part of the "pharmaceutical preparations" industry.
Sunshine Biopharma (NASDAQ:SBFM) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, community ranking, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.
Sunshine Biopharma has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -1.04, indicating that its share price is 204% less volatile than the S&P 500.
Evofem Biosciences has lower revenue, but higher earnings than Sunshine Biopharma. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.
Evofem Biosciences has a net margin of 290.81% compared to Evofem Biosciences' net margin of -18.70%. Evofem Biosciences' return on equity of -21.03% beat Sunshine Biopharma's return on equity.
42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 14.7% of Sunshine Biopharma shares are held by insiders. Comparatively, 0.2% of Evofem Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Evofem Biosciences received 261 more outperform votes than Sunshine Biopharma when rated by MarketBeat users. However, 100.00% of users gave Sunshine Biopharma an outperform vote while only 69.50% of users gave Evofem Biosciences an outperform vote.
Sunshine Biopharma currently has a consensus target price of $260.00, suggesting a potential upside of 30,852.38%. Given Evofem Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than Evofem Biosciences.
In the previous week, Evofem Biosciences' average media sentiment score of 0.00 equaled Sunshine Biopharma'saverage media sentiment score.
Summary
Sunshine Biopharma beats Evofem Biosciences on 9 of the 16 factors compared between the two stocks.
Get Evofem Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Evofem Biosciences Competitors List
Related Companies and Tools
